Corticorelin is a synthetic peptide that copies corticotropin-releasing hormone, the signal the hypothalamus sends to make the pituitary gland release adrenocorticotropic hormone (ACTH). It is used only as a diagnostic agent and is not a treatment. Marketed as Acthrel, corticorelin ovine triflutate is given as an intravenous injection, and the label describes it as a test of pituitary corticotroph responsiveness that helps tell a pituitary source of excess ACTH from an ectopic source in patients with ACTH-dependent Cushing's syndrome. A rise or absence of rise in blood ACTH and cortisol after the dose guides the interpretation. ChEMBL records it as a protein with a first approval in 1996, and its ATC code, V04CD04, places it among the diagnostic agents.
Facts
Classification
Approval Status Route of Administration First Approved / Isolated Year Connections
Treats
Source DailyMed, National Library of Medicine: Acthrel (corticorelin ovine triflutate) label, DailyMed
Sources
1. Corticorelin ovine triflutate (ChEMBL record)
ChEMBL molecule record CHEMBL1201591, first_approval field
"first_approval": 1996
ChEMBL molecule record CHEMBL1201591, max_phase 4.0 means approved
"max_phase": "4.0"
View the Source2. ChEMBL, EMBL-EBI: ChEMBL molecule record CHEMBL2108182 (Corticorelin)
ChEMBL, EMBL-EBIatc_classifications of the molecule record; ATC class derived from cited code V04CD04 (main group V)Quote, atc_classifications of the molecule record; ATC class derived from cited code V04CD04 (main group V)
"atc_classifications": [ "V04CD04" ], "molecule_chembl_id": "CHEMBL2108182", "pref_name": "CORTICORELIN"
View the Source 3. DailyMed, National Library of Medicine: Acthrel (corticorelin ovine triflutate) label, DailyMed
DailyMed, National Library of MedicineLabel header, route statement
For intravenous injection only
Treats: Cushing's Syndrome, Indications and usage; a diagnostic use, not a treatment
ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.